Logo image of ESPR

ESPERION THERAPEUTICS INC (ESPR) Stock Fundamental Analysis

USA - NASDAQ:ESPR - US29664W1053 - Common Stock

3.3 USD
+0.4 (+13.79%)
Last: 10/3/2025, 8:00:02 PM
3.28 USD
-0.02 (-0.61%)
After Hours: 10/3/2025, 8:00:02 PM
Fundamental Rating

2

ESPR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 196 industry peers in the Pharmaceuticals industry. ESPR has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, ESPR is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ESPR had negative earnings in the past year.
In the past year ESPR has reported a negative cash flow from operations.
ESPR had negative earnings in each of the past 5 years.
ESPR had a negative operating cash flow in each of the past 5 years.
ESPR Yearly Net Income VS EBIT VS OCF VS FCFESPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M

1.2 Ratios

ESPR's Return On Assets of -29.97% is in line compared to the rest of the industry. ESPR outperforms 52.55% of its industry peers.
Industry RankSector Rank
ROA -29.97%
ROE N/A
ROIC N/A
ROA(3y)-70.33%
ROA(5y)-64.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ESPR Yearly ROA, ROE, ROICESPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

1.3 Margins

ESPR's Gross Margin of 61.59% is fine compared to the rest of the industry. ESPR outperforms 69.39% of its industry peers.
In the last couple of years the Gross Margin of ESPR has remained more or less at the same level.
ESPR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.59%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.04%
GM growth 5YN/A
ESPR Yearly Profit, Operating, Gross MarginsESPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

1

2. Health

2.1 Basic Checks

ESPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
ESPR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ESPR has been increased compared to 5 years ago.
ESPR has a better debt/assets ratio than last year.
ESPR Yearly Shares OutstandingESPR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
ESPR Yearly Total Debt VS Total AssetsESPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -5.57, we must say that ESPR is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ESPR (-5.57) is worse than 60.71% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.57
ROIC/WACCN/A
WACC8.26%
ESPR Yearly LT Debt VS Equity VS FCFESPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M

2.3 Liquidity

ESPR has a Current Ratio of 1.15. This is a normal value and indicates that ESPR is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.15, ESPR is not doing good in the industry: 79.08% of the companies in the same industry are doing better.
A Quick Ratio of 0.76 indicates that ESPR may have some problems paying its short term obligations.
ESPR has a worse Quick ratio (0.76) than 82.65% of its industry peers.
Industry RankSector Rank
Current Ratio 1.15
Quick Ratio 0.76
ESPR Yearly Current Assets VS Current LiabilitesESPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 43.02% over the past year.
The Revenue has decreased by -3.49% in the past year.
The Revenue has been growing by 17.50% on average over the past years. This is quite good.
EPS 1Y (TTM)43.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.94%
Revenue 1Y (TTM)-3.49%
Revenue growth 3Y61.84%
Revenue growth 5Y17.5%
Sales Q2Q%11.58%

3.2 Future

The Earnings Per Share is expected to grow by 45.06% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 28.66% on average over the next years. This is a very strong growth
EPS Next Y67.9%
EPS Next 2Y37.9%
EPS Next 3Y29.6%
EPS Next 5Y45.06%
Revenue Next Year13.41%
Revenue Next 2Y2.55%
Revenue Next 3Y8.13%
Revenue Next 5Y28.66%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ESPR Yearly Revenue VS EstimatesESPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
ESPR Yearly EPS VS EstimatesESPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -2 -4 -6 -8 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ESPR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ESPR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ESPR Price Earnings VS Forward Price EarningsESPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ESPR Per share dataESPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as ESPR's earnings are expected to grow with 29.60% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.9%
EPS Next 3Y29.6%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ESPR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ESPERION THERAPEUTICS INC

NASDAQ:ESPR (10/3/2025, 8:00:02 PM)

After market: 3.28 -0.02 (-0.61%)

3.3

+0.4 (+13.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners50.61%
Inst Owner Change0%
Ins Owners0.4%
Ins Owner Change0.36%
Market Cap665.35M
Analysts77.14
Price Target6.21 (88.18%)
Short Float %12.37%
Short Ratio3.83
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)26.77%
Min EPS beat(2)-32.97%
Max EPS beat(2)86.52%
EPS beat(4)3
Avg EPS beat(4)24.32%
Min EPS beat(4)-32.97%
Max EPS beat(4)86.52%
EPS beat(8)5
Avg EPS beat(8)81.14%
EPS beat(12)8
Avg EPS beat(12)56.84%
EPS beat(16)11
Avg EPS beat(16)44.72%
Revenue beat(2)2
Avg Revenue beat(2)22.69%
Min Revenue beat(2)17.27%
Max Revenue beat(2)28.11%
Revenue beat(4)3
Avg Revenue beat(4)13.51%
Min Revenue beat(4)-1.37%
Max Revenue beat(4)28.11%
Revenue beat(8)7
Avg Revenue beat(8)23.82%
Revenue beat(12)9
Avg Revenue beat(12)15.29%
Revenue beat(16)12
Avg Revenue beat(16)14.05%
PT rev (1m)4.93%
PT rev (3m)5.19%
EPS NQ rev (1m)27.41%
EPS NQ rev (3m)-7.8%
EPS NY rev (1m)44.38%
EPS NY rev (3m)61.89%
Revenue NQ rev (1m)0.93%
Revenue NQ rev (3m)-0.94%
Revenue NY rev (1m)2.23%
Revenue NY rev (3m)8.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.48
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.49
EYN/A
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS1.33
BVpS-2.15
TBVpS-2.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.97%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.59%
FCFM N/A
ROA(3y)-70.33%
ROA(5y)-64.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.04%
GM growth 5YN/A
F-Score1
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 157.55%
Cap/Sales 0.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.15
Quick Ratio 0.76
Altman-Z -5.57
F-Score1
WACC8.26%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.94%
EPS Next Y67.9%
EPS Next 2Y37.9%
EPS Next 3Y29.6%
EPS Next 5Y45.06%
Revenue 1Y (TTM)-3.49%
Revenue growth 3Y61.84%
Revenue growth 5Y17.5%
Sales Q2Q%11.58%
Revenue Next Year13.41%
Revenue Next 2Y2.55%
Revenue Next 3Y8.13%
Revenue Next 5Y28.66%
EBIT growth 1Y-811.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-228.45%
EBIT Next 3Y5.65%
EBIT Next 5Y45.72%
FCF growth 1Y24.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.38%
OCF growth 3YN/A
OCF growth 5YN/A